Vaccine

S12.3 Understanding How Broadly Cross-Neutralising Antibodies Develop in HIV Infection - Clues For HIV Vaccine Development?
L Morris

Sexually Transmitted Infections Jul 2013, 89 (Suppl 1) A19; DOI: 10.1136/sextrans-2013-051184.0059
S12.2 Tales of Woe: HSV Vaccine and Null Study Results
A Wald

Sexually Transmitted Infections Jul 2013, 89 (Suppl 1) A19; DOI: 10.1136/sextrans-2013-051184.0058
P3.371 Reduction in HPV Prevalence Among Young Women Following Introduction of HPV Vaccine in the United States and Estimated Vaccine Effectiveness
L E Markowitz, S Hariri, C Lin, E Dunne, M Steinau, G McQuillan, E R Unger

Sexually Transmitted Infections Jul 2013, 89 (Suppl 1) A265; DOI: 10.1136/sextrans-2013-051184.0824
O01.5 Efficacy of RG1-VLP Vaccination Against Genital and Cutaneous Human Papillomaviruses in Vitro and in Vivo
C Schellenbacher, K Kwak, D Fink, S Shafti-Keramat, B Huber, C Jindra, R Roden, R Kirnbauer

Sexually Transmitted Infections Jul 2013, 89 (Suppl 1) A27-A28; DOI: 10.1136/sextrans-2013-051184.0087
O19.5 Assessing the Effectiveness of the Human Papillomavirus (HPV) Vaccination Programme in Victoria, Australia
S M Garland, S O Osborne, E J Young, J M L Brotherton, S N Tabrizi, D M Gertig, Y Jayasinghe

Sexually Transmitted Infections Jul 2013, 89 (Suppl 1) A64; DOI: 10.1136/sextrans-2013-051184.0195

Main menu